KIP lyophilisate for preparation of oral solution 300mg 1 dose vial, 5pcs

Composition

The drug is an immunologically active protein fraction isolated from human blood plasma of healthy donors, individually tested for the absence of antibodies to human immunodeficiency virus (HIV−1 and HIV−2) and hepatitis C virus and hepatitis B virus surface antigen (HBsAg). The drug has a low anti-complementary activity as a result of treatment with a small amount of pepsin in a slightly acidic medium, followed by removal of the enzyme with aluminum hydroxide.

Pharmacological action

The active component of the drug is immunoglobulins, which have the activity of antibodies of various specificity. The drug also has a non-specific activity, which manifests itself in increasing the body’s resistance.

Indications

-prevention of hepatitis A, measles, flu, whooping cough, meningococcal infection, polio; – treatment of hypo-and agammaglobulinemia; – to increase the body’s resistance during the convalescence of infectious diseases.

Use during pregnancy and lactation

During pregnancy or lactation, use according to vital indications, comparing the benefit to the mother and the risk to the fetus. Immunoglobulin penetrates into breast milk and can contribute to the transmission of protective antibodies to the newborn.

Contraindications

-allergic reactions or severe systemic reactions to human blood products in the anamnesis. In cases of severe sepsis, the only contraindication for the use of immunoglobulin is anaphylactic shock on a history of human blood products. With caution: severe heart failure, diabetes mellitus, kidney failure.

Side effects

When administered, the following symptoms may occur: headache, dizziness, migraine pain, abdominal pain, increased or decreased blood pressure, tachycardia, cyanosis, chills, shortness of breath, chest pain. In rare cases, reactions may develop in the form of hyperemia and an increase in body temperature to 37.5 °C during the first days after use, as well as dyspeptic phenomena. Individuals with altered reactivity may develop various types of allergic reactions, and in exceptional cases, anaphylactic shock. Rarely – marked decrease in blood pressure, collapse, loss of consciousness, increased sweating, fatigue, malaise, back pain, myalgia, numbness, fever or cold sensation, aseptic meningitis, acute necrosis of the renal tubules.

Interaction

Immunoglobulin therapy can be combined with other medications, in particular, antibiotics. In infants, do not use together with calcium gluconate. Immunoglobulin should be administered no earlier than 3 months after immunization with live viral vaccines against measles, rubella, mumps, and chickenpox.

Special instructions

People suffering from allergic diseases (bronchial asthma, atopic dermatitis, recurrent urticaria) or prone to allergic reactions on the day of use of immunoglobulin and for the next 8 days are recommended to prescribe antihistamines. During the period of exacerbation of the allergic process, the drug is administered according to the conclusion of an allergist. Individuals suffering from autoimmune diseases (blood diseases, connective tissue diseases, nephritis, etc. ) should be given the drug against the background of appropriate therapy. A temporary increase in the content of administered antibodies in the patient’s blood after use of immunoglobulin may cause false positive results of serological tests. Information about the possible effect of the drug on the ability to drive vehicles and mechanisms. use of the drug does not lead to psychomotor disorders and does not affect the ability to drive vehicles and other mechanisms.

Storage conditions

Store in a dry place protected from light at a temperature of 2 to 10°C. Keep out of reach of children

Shelf life

2 years

Active ingredient

Human immunoglobulin is normal

Conditions of release from pharmacies

By prescription

Dosage form

oral solution